Last reviewed · How we verify
nefopam, ketoprofen, paracetamol — Competitive Intelligence Brief
phase 3
NMDA receptor antagonist
NMDA receptor
Pain management
Small molecule
Live · refreshed every 30 min
Target snapshot
nefopam, ketoprofen, paracetamol (nefopam, ketoprofen, paracetamol) — American University of Beirut Medical Center. Nefopam is a non-opioid analgesic that acts as an NMDA receptor antagonist, inhibiting the release of pain-producing neurotransmitters.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| nefopam, ketoprofen, paracetamol TARGET | nefopam, ketoprofen, paracetamol | American University of Beirut Medical Center | phase 3 | NMDA receptor antagonist | NMDA receptor | |
| Namenda | MEMANTINE | AbbVie | marketed | N-methyl-D-aspartate Receptor Antagonist | Glutamate NMDA receptor; GRIN1/GRIN2A | 2003-01-01 |
| Felbatol | FELBAMATE | Mylan Speciality Lp | marketed | Anti-epileptic Agent [EPC] | NMDA receptor-ionophore complex | 1993-01-01 |
| QUINIDINE | QUINIDINE | marketed | sigma-1 receptor, NMDA receptor, CYP2D6 | 1950-01-01 | ||
| Methadone Hydrochloride | METHADONE | Specgx Llc | marketed | Opioid Agonist | mu-opioid receptors, NMDA receptor | 1947-01-01 |
| Intravenous Esketamine | Intravenous Esketamine | Janssen Research & Development, LLC | marketed | NMDA receptor antagonist | NMDA receptor (N-methyl-D-aspartate receptor) | |
| Ketofol(ketamine+propofol) | Ketofol(ketamine+propofol) | Post Graduate Institute of Medical Education and Research, Chandigarh | marketed | Fixed-dose combination anesthetic | NMDA receptor (ketamine); GABA-A receptor (propofol) |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape (NMDA receptor antagonist class)
- Turku University Hospital · 3 drugs in this class
- H. Lundbeck A/S · 2 drugs in this class
- Ciusss de L'Est de l'Île de Montréal · 2 drugs in this class
- Shalvata Mental Health Center · 2 drugs in this class
- New York State Psychiatric Institute · 2 drugs in this class
- Auris Medical AG · 1 drug in this class
- AstraZeneca · 1 drug in this class
- Alameda Health System · 1 drug in this class
- Centre Hospitalier Universitaire de Nice · 1 drug in this class
- Asker & Baerum Hospital · 1 drug in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- nefopam, ketoprofen, paracetamol CI watch — RSS
- nefopam, ketoprofen, paracetamol CI watch — Atom
- nefopam, ketoprofen, paracetamol CI watch — JSON
- nefopam, ketoprofen, paracetamol alone — RSS
- Whole NMDA receptor antagonist class — RSS
Cite this brief
Drug Landscape (2026). nefopam, ketoprofen, paracetamol — Competitive Intelligence Brief. https://druglandscape.com/ci/nefopam-ketoprofen-paracetamol. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab